Knowledgebase‐Driven Exploration and Experimental Verification of Simvastatin's Inhibitory Impact on P2X7 / NLRP3 Inflammasome Pathway
Chemical Biology & Drug Design · 2025
DOI: 10.1111/cbdd.70048 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Xinhai Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacology Sciences, Zhejiang University of Technology, Hangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Simvastatin, NLR Family, Pyrin Domain-Containing 3 Protein, Receptors, Purinergic P2X7, Inflammasomes. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 53 Literaturangaben. Gefördert von: Natural Science Foundation of Zhejiang Province, Welfare Technology Application Plan of Zhejiang Province, Special Project of Science and Technology of Zhejiang Province, China.
Abstract (Originalsprache)
Depression is a mental health disorder and is the fourth most prevalent disease. Previous studies have suggested that statins are involved in the reduction of neuroinflammation. However, the potential mechanism for this relationship is unclear. The current study aimed to elucidate this by examining the effects of simvastatin on the P2X7/NLRP3 pathway in rats exposed to chronic mild stress (CMS). To achieve this goal, a depression database was first constructed, and simvastatin was used as an input to predict potential targets using machine/deep learning methods. Interestingly, the P2X7/NLRP3 pathway was predicted as a potential target for simvastatin. Subsequently, a depression rat model was established by inducing CMS for 4 weeks. Behavioral changes were detected via a sucrose preference test and forced swim test. The depression rats were then treated with simvastatin (10 mg/kg/day) for 14 days. Following treatment, changes in behavior and the activation of the NLRP3/ASC/caspase‐1 inflammasome pathway in the depression model rats were observed. The P2X7 agonist (ATP) and selective P2X7 antagonist brilliant blue G (BBG) were also used for in vivo intervention. Data from the experiment showed that treatment with simvastatin and BBG significantly reduced the depressive‐like behaviors in depression model rats, as well as the protein and mRNA expression levels of P2X7 and NLRP3 inflammasome. The protein and mRNA levels of the pro‐inflammatory cytokine interleukin‐1β significantly increased. These results demonstrate that simvastatin exerted an antidepressant‐like effect in the CMS model of rats, and this effect was dependent on the inhibition of the P2X7/NLRP3 inflammasome pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Pharmacology Sciences, Zhejiang University of Technology, Hangzhou, People's Republic of China.
- Guangxi Institute for Food and Drug Control, Nanning, People's Republic of China.
ORCID-Profile: Yan Chen
Förderung
- Natural Science Foundation of Zhejiang Province
- Welfare Technology Application Plan of Zhejiang Province
- Special Project of Science and Technology of Zhejiang Province, China
Zitieren
APA
Wu, X., Guo, C. X., Wang, S. F., Gong, T. T., Yao, J. W., Hu, L., Deng, Z. Y., Tang, L., Xie, P., Zhang, Z., & Chen, Y. (2025). Knowledgebase‐Driven Exploration and Experimental Verification of Simvastatin's Inhibitory Impact on P2X7 / NLRP3 Inflammasome Pathway. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70048
Vancouver
Wu X, Guo CX, Wang SF, Gong TT, Yao JW, Hu L, et al. Knowledgebase‐Driven Exploration and Experimental Verification of Simvastatin's Inhibitory Impact on P2X7 / NLRP3 Inflammasome Pathway. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70048
BibTeX
@article{Wu2025,
author = {Wu, Xinhai and Guo, Chen-Xin and Wang, Sheng-Feng and Gong, Ting-Ting and Yao, Jing-Wei and Hu, Lin and Deng, Zu-Yue and Tang, Lan and Xie, Peng and Zhang, Zan and Chen, Yan},
title = {Knowledgebase‐Driven Exploration and Experimental Verification of Simvastatin's Inhibitory Impact on P2X7 / NLRP3 Inflammasome Pathway},
journal = {Chemical Biology & Drug Design},
year = {2025},
doi = {10.1111/cbdd.70048}
}
EUVIMED